Caribou Biosciences (CRBU) vs Kalaris Therapeutics (KLRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kalaris Therapeutics (KLRS) has outperformed Caribou Biosciences (CRBU) over the past year, losing 62.1% versus a loss of 82.0%. Over five years, CRBU leads with a -97.7% price change compared with -99.5% for KLRS. Kalaris Therapeutics is the larger company by market cap ($59.5 million vs $51.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBU | KLRS |
|---|---|---|
| Share price | $0.4812 | $2.50 |
| Market cap | $51.59M | $59.51M |
| 1-day change | -22.06% | -2.34% |
| YTD return | -69.74% | -70.38% |
| 1-year return | -82.04% | -62.06% |
| 5-year return | -97.69% | -99.51% |
| EPS (TTM) | $-1.08 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.54 | $11.88 |
| 52-week low | $0.45 | $2.35 |
| Distance from 52-week high | -86.39% | -78.96% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +1094.93% | +648.40% |
| Average volume | 2.14M | 252.88K |
| Shares outstanding | 107.21M | 23.80M |
| Employees | 97 | 20 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KLRS has outperformed CRBU by 20.0 percentage points over the past year.
About Caribou Biosciences
CRBU stock →Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 97 employees
About Kalaris Therapeutics
KLRS stock →Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
CRBU vs KLRS FAQ
Which is bigger, Caribou Biosciences or Kalaris Therapeutics?
Kalaris Therapeutics (KLRS) is larger, with a market capitalization of $59.51M compared with $51.59M for Caribou Biosciences (CRBU).
Which stock has performed better over the past year, CRBU or KLRS?
KLRS returned -62.06% over the past 12 months, compared with -82.04% for CRBU (price return, excluding dividends). Past performance does not predict future results.
Are Caribou Biosciences and Kalaris Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.